December News Briefs

Insight Genetics launched a new CLIA-certified laboratory, Insight Molecular Labs. The new lab offers diagnostic tests that identify specific cancer biomarkers. It provides clinical trial support services for targeted therapeutics, assisting in the identification of appropriate patients for trials, and specializes in the detection and monitoring of drug resistance in patients being treated with specific cancer therapies. Press release 

Linguamatics announced that Huntsman Cancer Institute (HCI) at the University of Utah has deployed its natural language processing based I2E software platform to transform the immense stores of unstructured text in electronic health records into actionable information to drive improvements in cancer research, treatments and outcomes. HCI is using I2E with its in-house clinical informatics infrastructure to extract data from the unstructured text contained in surgical, pathology, radiology, and clinical notes related to hematology oncology disease areas. Press release 

YarcData, a Cray company, entered a collaborative effort with Selventa, a leading provider of systems diagnostics for personalized medicine. Selventa will have access to YarcData’s big data analytics appliance, Urika, to help pharmaceutical organizations better target drugs and accelerate market delivery. Because data loaded into Urika does not need to be partitioned by disease area, the collaboration will enable analysis to be performed across larger or combined data sets, making it possible to find previously unknown relationships between genes and proteins, treatments and disease mechanisms, human and animal biology, diseased tissue and blood, as well as identification of biomarkers representative of predictive and prognostic indications. Press release 

Myriad Genetics announced it will present data from four clinical studies with Prolaris at the 14th Annual Meeting of the Society for Urologic Oncology (SUO) in Bethesda, MD. Prolaris is a prognostic test that predicts cancer-specific disease progression and mortality based on an analysis of 46 cell cycle progression genes. Myriad’s data will demonstrate the ability of the Prolaris test to accurately stratify a prostate cancer patient's risk of having an aggressive form of the disease.  Another new study in renal cell carcinoma also will be presented at the SUO meeting, demonstrating that Myriad's cell cycle progression gene panel predicts metastatic progression in patients with this cancer. Press release 

Clinovo will release an exclusive preview of two new features to its open source Electronic Data Capture (EDC) system ClinCapture at the 2014 Outsourcing in Clinical Trials West Coast conference in January. The new features are Medical Coding, enabling users to appropriately categorize medical terms entered in ClinCapture; and Risk-based Monitoring, allowing ClinCapture to integrate with Patient Profiles to create individual reports for each subject. Patient Profiles automatically runs algorithms to mine clinical data and identify data that is unusual. PRWeb 



Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.